Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, is reporting on its financial results for the third quarter ended Sept. 30, 2023; the report also included key business updates. Financial numbers to note in the report … Continue reading InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q3 2023 Financial Report, Reports Possible Adjustment of Facility Terms by EIB